Experts develop commercial formulation Campto® for colorectal cancer

Announcing a new publication for Acta Materia Medica journal. The compound 7-ethyl-10-hydroxy-camptothecin (SN38) is a broad-spectrum antitumor agent whose applications are greatly limited by its poor solubility. Therefore, irinotecan, the hydrophilic derived prodrug of SN38, has been developed as the commercial formulation Campto® for colorectal cancer.

Cancer Research eBook

Compilation of the top interviews, articles, and news in the last year.
Download a free copy

However, only 1% to 0.1% of irinotecan is converted to active SN38 in vivo, thus leading to unsatisfactory antitumor activity in clinical settings. The authors of this article report a smart stimuli-responsive SN38 prodrug nanoassembly for efficient cancer therapy. First, SN38 was conjugated with an endogenous lipid, cholesterol (CST), via a redox dual-responsive disulfide bond (namely SN38-SS-CST). The prodrug self-assembled into uniform prodrug nanoassemblies with good colloidal stability and ultrahigh drug loading. SN38-SS-CST NPs released sufficient SN38 in the redox environments of tumor cells but remained intact in normal tissues.

Finally, SN38-SS-CST NPs potently inhibited the growth of colon cancer without causing systemic toxicity, thus indicating their promise as a translational chemotherapeutic nanomedicine.


Compuscript Ltd

Posted in: Medical Research News | Medical Condition News

Tags: Cancer, Cancer Therapy, Cholesterol, Colon Cancer, Colorectal, Colorectal Cancer, Compound, in vivo, Irinotecan, Nanomedicine, Research, Tumor

Comments (0)

Source: Read Full Article